“Metagenics is committed to bringing the benefits of therapeutic nutritional products and lifestyle therapy to millions of patients and healthcare practitioners around the globe, aiding in the fight against chronic illness.”
San Clemente, California-based life sciences company, Metagenics, Inc., has announced executive appointments to lead the company to achieve their accelerated growth plans. Metagenics is committed to bringing the benefits of therapeutic nutritional products and lifestyle therapy to millions of patients and healthcare practitioners around the globe, aiding in the fight against chronic illness.
Effective August 16, the Metagenics’ Board of Directors is appointing Metagenics’ Founder and CEO Jeff Katke as Chairman of the Board of Directors, and Fred Howard, an executive with extensive experience in managing fast-growing consumer healthcare companies, as the new CEO.
“As CEO of Metagenics, Fred will be responsible for all management and affairs of the company and for driving the business to achieve our ambitious growth goals. He will report to the Metagenics’ Board of Directors. Jeff Katke will be focused on critical strategic relationships with the medical, insurance, and government communities that will drive broad acceptance of therapeutic lifestyle management,” stated Jim Weaver, current Metagenics Board Chairman. Weaver will continue to serve on the Board of Directors as Vice Chairman.
“After 27 years of pioneering the scientific research and development of therapeutic nutritional products and lifestyle therapy, Metagenics is today at the epicenter of intersecting forces that are shaping 21st century healthcare to incorporate lifestyle medicine,” said Katke. “The cost of chronic illness is depleting our healthcare resources. But there is now significant medical research and evidence showing that lifestyle medicine is effective in preventing and treating these illnesses. Metagenics is poised for exponential growth as our breakthrough medical foods, products and services are broadly adopted as the therapies of choice.”
Fred Howard, the new CEO, comes to Metagenics from Carl Zeiss Vision, where he was President of the Americas, Australia and New Zealand, responsible for marketing, sales, prescription manufacturing and operations. At Zeiss, he led the advancements for eyewear, prescription lenses and coatings, lab services and equipment, strengthening the company’s formidable brand, introducing a stream of products and driving commercial innovations and sustainable success.
Howard’s background also includes 25 years at Procter & Gamble, Gillette and Richardson-Vicks. Most recently as Senior Vice President for Gillette, North America, he was responsible for the Oral-B® and Braun® franchises. In the course of his career, Howard has run businesses around the globe. For two years he lived in Australia, where he was responsible for the suite of Gillette products, including Gillette® blades and razors, Duracell®, Papermate®, Oral-B and Braun.
“The new structure and focus of our leadership comes at a time when Metagenics has the science, the products and the resources to transform the healthcare landscape with real solutions to the epidemic of metabolic syndrome, diabetes, cardiovascular disease and other lifestyle-related conditions,” noted Jeffrey Bland, PhD., FACN, CNS, Chief Science Officer for Metagenics.
Bland cited the remarkable results of a clinical trial recently conducted by three major universities and sponsored by Metagenics. This multi-center trial demonstrated the power of FirstLine Therapy®, Metagenics’ turn-key therapeutic lifestyle change program combined with its proprietary medical food UltraMeal® PLUS 360°, in improving multiple biomarkers of metabolic syndrome, a condition exhibited by 50 million Americans that leads to diabetes and cardiovascular illness. In these studies, Metagenics’ medical food UltraMeal PLUS 360°, used with diet and exercise, produced significantly more improvement than just diet and exercise alone.
Major health organizations including the U. S. Centers for Disease Control and Prevention and the American Heart Association recommend lifestyle therapy, including a healthy diet and exercise, as the preferred therapy in treating metabolic syndrome. Metagenics’ medical foods have been shown to enhance the benefits and compliance with a healthy diet and exercise, and provide a more efficacious and cost effective solution to managing the metabolic syndrome patient.
About Metagenics, Inc.
Metagenics, Inc. (www.metagenics.com), headquartered in San Clemente, CA, is a global life sciences company focused on reversing chronic illness and improving health. Metagenics also supports healthcare practitioners in incorporating lifestyle medicine into their practices, offering education and practice management programs such as FirstLine Therapy® to assist them in this transition. More than 75,000 healthcare professionals in North America, Australia, New Zealand, Europe, South America, South Africa and Asia use Metagenics’ products to help their patients achieve a lifetime of good health. Founded in 1983, the company currently holds more than 40 proprietary formula patents. Today, Metagenics continues its leadership role by successfully merging nutritional genomics, functional medicine, and lifestyle medicine to develop solutions to society's most pressing health concerns. In August, 2009, Metagenics entered into a joint venture with Alticor (www.alticor.com), a global leader in the nutrition and wellness industry. Alticor is an $8B corporation offering products, business opportunities, product development, manufacturing and logistic services in more than 80 countries and territories worldwide. Both Metagenics and Alticor share a philosophy for promoting good nutrition, healthy living and natural science.